AMMAN — The
Jordan Food and Drug Administration (JFDA) has concluded an initial draft to revise the basis for
drug pricing rules, aligning with Royal directives to ensure medicine
accessibility. In a statement on Sunday, the JFDA shared that this step is part
of its ongoing plan to continually study and enhance drug pricing rules, aiming
to enhance
drug security and affordability for citizens.
اضافة اعلان
Nizar
Mheidat, the Director General of
JFDA, explained that the amendments involve
reviewing the price lists of reference drug pricing countries and selecting
nations with comparable economic conditions, income levels, and populations to
Jordan's, the Jordan News Agency, Petra reported.
He
further highlighted that the plan seeks to adhere to
global pricing principles
while considering the Kingdom's unique pharmaceutical market dynamics.
Mheidat
pointed out that these changes explore recalculating profit margins across
various price categories, thereby potentially reducing drug costs.
He
also emphasized that the draft will contribute to extending the patient
assistance program to cover expensive medications for chronic diseases and
introduce mechanisms to support the local industry, particularly in relation to
biological and advanced medicines.
Read more National news
Jordan News
.jpg)
.jpg)
